Anacor Pharma (ANAC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anacor Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 6, 2015 4:00 PM EDTRecognized $17.8 million in total KERYDIN® revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015 Crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies in patients with mild-to-moderate atopic dermatitis and demonstrated a safety profile consistent with previous studies Anacor expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first... More
